AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19214123 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir (SQV/r) and Lopinavir/ritonavir (LPV/r)
Number of subjects: 337
Study 17626759 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi injection after operation
Number of subjects: 60
Study 17626759 — intervention group
Group type: COMPARATOR
Intervention: No immune supportive treatment (Control)
Number of subjects: 60
Study 15595909 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease management model of transitional care
Number of subjects: 166
Study 11718454 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with beta-carotene (6 mg), vitamin E (30 mg), vitamin C (120 mg), selenium (100 microg), and zinc (20 mg) for 2 years
Number of subjects: 1000
Study 11718454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 9428250 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic-resonance pelvimetry (reported to obstetricians)
Number of subjects: 235
Study 9428250 — intervention group
Group type: COMPARATOR
Intervention: Control group (pelvimetry results not disclosed)
Number of subjects: 235
Study 8483620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (5 mg/kg twice daily for 10 days)
Number of subjects: 578
Study 8483620 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (13.4 mg/kg three times daily for 10 days)
Number of subjects: 578
Study 8483620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 578
Study 8483620 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 578
Study 3316538 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 269
Study 3316538 — intervention group
Group type: COMPARATOR
Intervention: Strict controls
Number of subjects: 269
Study 3316538 — intervention group
Group type: COMPARATOR
Intervention: All controls
Number of subjects: 269
Study 3316538 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated subjects
Number of subjects: 269
Study 28988159 — intervention group
Group type: EXPERIMENTAL
Intervention: CC+SI
Number of subjects: 2
Study 28988159 — intervention group
Group type: COMPARATOR
Intervention: 3:1 C:V
Number of subjects: 2
Study 26505570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (10 mL, 75 mg)
Number of subjects: 163
Study 25391305 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin group (400 µg folic acid and 500 µg vitamin B12 daily)
Number of subjects: 2919
Study 25391305 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2919
Study 22285894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task Switch Exercise (DSE)
Number of subjects: 18
Study 22285894 — intervention group
Group type: COMPARATOR
Intervention: Control (steady-state walking training)
Number of subjects: 18
Study 20861296 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ-I (IPF-specific version of the St George's Respiratory Questionnaire)
Number of subjects: 158
Study 20861296 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ-I
Number of subjects: 158
Study 20861296 — intervention group
Group type: COMPARATOR
Intervention: Original SGRQ
Number of subjects: 158
Study 18795524 — intervention group
Group type: EXPERIMENTAL
Intervention: White ProRoot Mineral Trioxide Aggregate (WMTA)
Number of subjects: 48
Study 18795524 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 48
Study 15904552 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on intercultural communication for GPs and patients, including training on cultural differences and a videotaped instruction for patients on communication.
Number of subjects: 2407
Study 15904552 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on intercultural communication for GPs and patients.
Number of subjects: 2407
Study 12888775 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of encapsulated dried leaf
Number of subjects: 20
Study 12888775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of encapsulated dried leaf
Number of subjects: 20
Study 12888775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg of encapsulated dried leaf
Number of subjects: 20
Study 12888775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10598599 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hyperventilation
Number of subjects: 30
Study 10598599 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 30
Study 7862473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous nasal beclomethasone (336 micrograms/day)
Number of subjects: 17
Study 7862473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous nasal beclomethasone (168 micrograms/day)
Number of subjects: 17
Study 7862473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7862473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous nasal beclomethasone
Number of subjects: 17
Study 1945637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar
Number of subjects: 26
Study 1945637 — intervention group
Group type: COMPARATOR
Intervention: Saccharin
Number of subjects: 26
Study 1945637 — intervention group
Group type: COMPARATOR
Intervention: Aspartame
Number of subjects: 26
Study 7039940 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan (M)
Number of subjects: 38
Study 7039940 — intervention group
Group type: COMPARATOR
Intervention: CAF (adriamycin, 5-fluorouracil and cyclophosphamide)
Number of subjects: 38
Study 30846665 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide measurement feedback and standard brief motivation
Number of subjects: 160
Study 30846665 — intervention group
Group type: COMPARATOR
Intervention: Standard brief motivational strategy
Number of subjects: 160
Study 26219195 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (CRM)
Number of subjects: 60
Study 26219195 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 60
Study 26219195 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-Metronidazole (CHX-MTZ)
Number of subjects: 60
Study 25377585 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M ESPE Clinpro XT Varnish (n=35)
Number of subjects: 136
Study 25377585 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifluorid (n=37)
Number of subjects: 136
Study 25377585 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluftored (n=23)
Number of subjects: 136
Study 25377585 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 136
Study 22959103 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐CRA (Laser-induced chorioretinal venous anastomosis)
Number of subjects: 55
Study 19179968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b monotherapy (1.5 micro g/kg/wk for 48 weeks)
Number of subjects: 126
Study 19179968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b monotherapy
Number of subjects: 126
Study 19179968 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (pegylated interferon alfa-2b + lamivudine 100 mg/d)
Number of subjects: 126
Study 17401588 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐self‐tapping Ankylos implants
Number of subjects: 263
Study 17401588 — intervention group
Group type: COMPARATOR
Intervention: Self‐tapping Camlog implants
Number of subjects: 263
Study 17401588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 263
Study 15257187 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg) and Indapamide (0.625 mg)
Number of subjects: 146
Study 15257187 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 146
Study 15257187 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide
Number of subjects: 146
Study 11219481 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release clarithromycin (two 500-mg tablets once daily for 7 days)
Number of subjects: 287
Study 11219481 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (one 875-mg tablet twice daily for 10 days)
Number of subjects: 287
Study 11219481 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release clarithromycin
Number of subjects: 287
Study 11219481 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 287
Study 9510706 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured patient‐centred education programme
Number of subjects: 40
Study 9510706 — intervention group
Group type: COMPARATOR
Intervention: Usual ad hoc information
Number of subjects: 40
Study 8287747 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein level higher than 2.5 mg/dl (Group A)
Number of subjects: 56
Study 8287747 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein level lower than 2.5 mg/dl (Group B)
Number of subjects: 56
Study 8287747 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein level in nonspecific abdominal pain (Group C)
Number of subjects: 56
Study 8287747 — intervention group
Group type: COMPARATOR
Intervention: Diseases other than acute appendicitis (Group D)
Number of subjects: 56
Study 3174047 — intervention group
Group type: EXPERIMENTAL
Intervention: disk-repositioning onlays
Number of subjects: 63
Study 3174047 — intervention group
Group type: COMPARATOR
Intervention: flat occlusal splint
Number of subjects: 63
Study 3174047 — intervention group
Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 63
Study 31630923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfaith-based abstinence-only intervention
Number of subjects: 613
Study 31630923 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-based abstinence-only intervention
Number of subjects: 613
Study 31630923 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 613
Study 29181880 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutment
Number of subjects: 15
Study 29181880 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutment
Number of subjects: 15
Study 29181880 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold alloy abutment
Number of subjects: 15
Study 29181880 — intervention group
Group type: COMPARATOR
Intervention: Control (Titanium)
Number of subjects: 15
Study 29181880 — intervention group
Group type: COMPARATOR
Intervention: Control (Zirconia)
Number of subjects: 15
Study 27234409 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf) administered twice daily by gastric gavage from day 1-28 of life
Number of subjects: 21
Study 27234409 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf)
Number of subjects: 21
Study 27234409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (excipient)
Number of subjects: 21
Study 25582960 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week home-based resistance training program
Number of subjects: 26
Study 23316290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR (1.6 to 4.8 mg/day)
Number of subjects: 3070
Study 23316290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3070
Study 20059527 — intervention group
Group type: EXPERIMENTAL
Intervention: THP-COP
Number of subjects: 53
Study 18713890 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen with air (G0)
Number of subjects: 137
Study 18713890 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N(2)O with oxygen (G50)
Number of subjects: 137
Study 18713890 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N(2)O with oxygen (G70)
Number of subjects: 137
Study 16897910 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-administered survey
Number of subjects: 334
Study 16897910 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 334
Study 16897910 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire
Number of subjects: 334
Study 12942855 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous trajectory of psychotropic drug consumption (uninterrupted consumption during the 5-year follow-up)
Number of subjects: 286
Study 12942855 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional trajectory of psychotropic drug consumption (interruption of consumption for at least 1 month)
Number of subjects: 286
Study 10321394 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise programme
Number of subjects: 27
Study 10321394 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 27
Study 8911887 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg) with grapefruit juice (250 ml)
Number of subjects: 12
Study 8911887 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg) with water
Number of subjects: 12
Study 1887983 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine
Number of subjects: 20
Study 1887983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 20
Study 1887983 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 20
Study 1887983 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 20
Study 6961737 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (1.6 g/100 kcal)
Number of subjects: 48
Study 6961737 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 1 (2.3 g/100 kcal)
Number of subjects: 48
Study 6961737 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula 2 (3.0 g/100 kcal)
Number of subjects: 48
Study 6961737 — intervention group
Group type: COMPARATOR
Intervention: Control (Human milk)
Number of subjects: 48
Study 6961737 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study 31499415 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil 25 mg three times daily
Number of subjects: 105
Study 31499415 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulants
Number of subjects: 66406
Study 30646105 — intervention group
Group type: COMPARATOR
Intervention: No stimulants
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term concurrent stimulant-opioid use
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 30s
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 40s
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 50s
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic white
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the southern United States
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse disorder
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorder
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 66406
Study 30646105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease
Number of subjects: 66406
Study 27323793 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 100
Study 27323793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24532143 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group, n = 59)
Number of subjects: 119
Study 24532143 — intervention group
Group type: COMPARATOR
Intervention: No haloperidol (control group, n = 60)
Number of subjects: 119
Study 24532143 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group)
Number of subjects: 119
Study 24532143 — intervention group
Group type: COMPARATOR
Intervention: No haloperidol (control group)
Number of subjects: 119
Study 22188327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic tips
Number of subjects: 39
Study 22188327 — intervention group
Group type: EXPERIMENTAL
Intervention: Masserann kit
Number of subjects: 39
Study 22188327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 39
Study 20056480 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine once-a-week (A)
Number of subjects: 38
Study 20056480 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine once-a-day (B)
Number of subjects: 38
Study 20056480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine once-a-day (C)
Number of subjects: 38
Study 20056480 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine once-a-day (B) and Lamivudine once-a-day (C)
Number of subjects: 38
Study 17236758 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 mcg b.i.d.
Number of subjects: 489
Study 17236758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 16167253 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser coagulation (laser group, n=46)
Number of subjects: 86
Study 16167253 — intervention group
Group type: COMPARATOR
Intervention: Hemorrhoidectomy (control group, n=40)
Number of subjects: 86
Study 11960538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 85) with tailored recommendations about optimizing dialysis prescriptions, expedited conversion of catheters to grafts/fistulas, and patient education.
Number of subjects: 169
Study 11960538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 85) with tailored recommendations.
Number of subjects: 169
Study 9857880 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal GTN, 0.6 mg/h
Number of subjects: 15
Study 8559862 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia with neutral phrases (color blue or yellow combined with objects ball or kite)
Number of subjects: 36
Study 1977646 — intervention group
Group type: EXPERIMENTAL
Intervention: Filshie clip
Number of subjects: 200
Study 1977646 — intervention group
Group type: COMPARATOR
Intervention: Pomeroy method
Number of subjects: 200
Study 344084 — intervention group
Group type: EXPERIMENTAL
Intervention: Trancopal (two tablets at night for two weeks)
Number of subjects: 85
Study 344084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets at night for two weeks)
Number of subjects: 85
Study 344084 — intervention group
Group type: EXPERIMENTAL
Intervention: Trancopal
Number of subjects: 85
Study 31491106 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized compiler for Hamiltonian simulation
Number of subjects: 3
Study 31491106 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase estimation at chemical accuracy
Number of subjects: 3
Study 28162781 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular corticosteroids alone
Number of subjects: 207
Study 28162781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroids plus methotrexate
Number of subjects: 207
Study 24801567 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged group during swing phase walking
Number of subjects: 30
Study 24801567 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged group
Number of subjects: 30
Study 24801567 — intervention group
Group type: COMPARATOR
Intervention: Facilitated swing-phase H-reflex group
Number of subjects: 30
Study 23819219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-apex blood-letting (5-6 blood drops/time, once daily for 3 times)
Number of subjects: 102
Study 23819219 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (local application of hydrochloric levofloxacin and erycin ointment, plus local warm compress)
Number of subjects: 102
Study 23819219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-apex blood-letting
Number of subjects: 102
Study 21480953 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI prompt group
Number of subjects: 196
Study 21480953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 21480953 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI prompt pharmacies
Number of subjects: 196
Study 21480953 — intervention group
Group type: COMPARATOR
Intervention: Control pharmacies
Number of subjects: 196
Study 19861603 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ± 1 bites of Anopheles albimanus mosquitoes infected with P. vivax
Number of subjects: 18
Study 19861603 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 ± 1 bites of Anopheles albimanus mosquitoes infected with P. vivax
Number of subjects: 18
Study 19861603 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 ± 1 bites of Anopheles albimanus mosquitoes infected with P. vivax
Number of subjects: 18
Study 19861603 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 volunteer exposed to eight mosquito bites)
Number of subjects: 18
Study 16555151 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical excision
Number of subjects: 44
Study 16555151 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative operation
Number of subjects: 44
Study 16555151 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory operation
Number of subjects: 44
Study 16555151 — intervention group
Group type: COMPARATOR
Intervention: Synchronous hepatic metastasis risk factors
Number of subjects: 44
Study 14747278 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (3 times per week for 6 weeks, 30 min per session)
Number of subjects: 17
Study 14747278 — intervention group
Group type: COMPARATOR
Intervention: Control (untrained leg)
Number of subjects: 17
Study 11378948 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming therapy
Number of subjects: 338
Study 11378948 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 338
Study 9009975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (stepped plan from 1 evening injection to multiple daily injections)
Number of subjects: 153